

International Journal of Biomed Research

Open Access

Research Article

Bhaskar Bhadra *

Optimization and validation of multiplex-PCR method for diagnosis of SARS-CoV-2

Abhishek M. Kulkarni¹, Vikas K. Patel¹, Akshay C. Chawande¹, Kenny Paul¹, Manish R. Shukla¹, Bhaskar Bhadra^{1*}, Santanu Dasgupta¹ ¹Synthetic Biology group, Reliance Corporate Park, Reliance Industries Limited, Navi Mumbai 400701, India *Corresponding Author: Bhaskar Bhadra, Synthetic Biology group, Reliance Corporate Park, Reliance Industries Limited, Navi Mumbai 400701, India

Received Date: May 05, 2021; Accepted Date: May 12, 2021; Published Date: June 03, 2021

Citation: Abhishek M. Kulkarni, Vikas K. Patel, Akshay C. Chawande, Paul K, Manish R. Shukla, Bhadra B., Dasgupta S. (2021) Optimization and validation of multiplex-PCR method for diagnosis of SARS-CoV-2; *International J. of Biomed Research*. 1(4); **DOI:** 10.31579/IJBR-2021/019 **Copyright:** © 2021, Bhaskar Bhadra, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The recent outbreak of COVID 19 pandemic caused by SARS-CoV-2 Coronaviruses claimed millions of lives across the globe. Early diagnosis of the infection is crucial to curb the community spread and enforcing strict quarantine procedure. Real time polymerase chain reaction (RT PCR) based diagnosis is considered as gold standard, however, is resource intensive. We, therefore, developed a PCR based efficient and specific diagnosis method for detection of SARS-CoV-2. We analysed over 100 genomes of SARS-CoV-2 and identified unique consensus sequences for designing PCR primers and evaluated them. Finally, we could optimize the one-step multiplex PCR directly from the extracted RNA and specific primers of envelope protein (E), nucleocapsid protein (N), and membrane protein (M) of SARS-CoV-2. The PCR products were visualized either in agarose gel or in Bioanalyzer. This method showed more than 95% accuracy compared to RT PCR tests, and therefore, is applicable in most of academic as well as pathological laboratory.

Keywords: SARS-CoV-2, COVID 19, one-step multiplex PCR, structural genes, bioanalyzer, signature sequences

Introduction:

In humans and birds, coronaviruses cause deadly diseases of respiratory tracts that can range from mild to lethal [1]. Among humans, common cold with headache if mild illnesses while lethal cases can cause MERS or SARS it emerged as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2002 and 2012 respectively which alternatively caused severe threats to public health [2]. In the late December 2019, another zoonotic form of human coronavirus was emerged in Wuhan, Hubei Province of China, and identified as SARS-CoV-2 that resulted in an outbreak of Coronavirus Disease 2019 (COVID-19) [3]. Since this outbreak, COVID-19 pandemic infected more than 37 million people globally resulted in death of more than one million people [4]. Recent studies showed that about 30% of infected individuals by SARS-CoV-2 remain asymptomatic [5]. These asymptomatic patients act as carriers which may unknowingly infect a mass of population [6]. Therefore, it became necessary to test as many individuals as possible from the various communities to diagnose for SARS-CoV-2 infection.

COVID 19 can be diagnosed by serological or nucleic acid detectionbased assays. Serological assays mainly depend on the detection of antibodies against the spike protein in the serum of infected individuals [7]. Serological assays have some limitations, as very less is known about the nature of immune response to SARS-CoV-2 infection and the scientific basis for durable immunity is not so well developed [8]. Though the assays depending on the detection of antibodies against the viral proteins are useful for serosurveillance, not all are suitable for diagnosis of SARS-CoV-2 due to poor understanding of the antibody responses against SARS-CoV-2 and lack of clarity about the clinical utility of serological testing [9]. Among humans, antibodies usually appear after 5 to 7 days after exposure to the SARS-CoV-2 [10]. During this time, infected individual may continue to spread the infectious viral particles to others and unknowingly infect public [6]. Nucleic acid-based assays are popular choice due to its high accuracy compared to various available serological assays for COVID-19 [11]. Antigen tests are also less sensitive and could be less reliable in case of clinical diagnosis of COVID-19 patients with low viral load [12]. Furthermore, nucleic acid-based assays provide quick results confirmation about infection in comparison to serological tests as the later works on the availability of SARS-CoV-2 protein in infected person.

SARS-CoV-2 is a positive sense single stranded RNA virus having the genome size of about 30 Kb which comprises 11 open reading frames (ORF) [13]. The 5' of most of ORF encodes a polyprotein which is processed by a virally encoded protease into 15 small peptides, including the RNA dependent RNA polymerase (RdRp) and a non-structural Protein 1 (NSP1). The Envelope (E), Spike (S) and Nucleocapsid (N) genes are encoded by unique independent ORFs [14]. Surface glycoprotein or spike (S) is the longest of these four proteins, it interacts with the host's angiotensin-converting enzyme 2 (ACE2) receptor and initiates the cascade of reaction that alternatively causes the infection, therefore, it plays a crucial role in rapid transmission from human to human [15]. Nucleoprotein (N) or Nucleocapsid phosphoprotein or interacts with the viral genome and M protein during virion assembly and

plays important role in improving the efficiency of sub-genomic viral RNA transcription and viral replication [16]. Small envelope membrane protein (E) like M protein, forms pentameric protein-lipid pores which allow ion-transport and self-assembles inside the host membranes. It also plays a vital role in virus assembly and morphogenesis [17].

Smaller genome size of SARS-CoV-2 makes it prone to accumulate mutations at a much higher rate compared to the organisms having larger genome size. After several rounds of replications in a mass of population, viruses may accumulate a variety of mutations which could result in the loss of infectivity [18]. Single stranded RNA viruses (ss RNA) have higher mutation rates than DNA viruses [19].

Recent advances in polymerase chain reaction (PCR), have allowed scientists for more reliable detection of pathogen for surveillance and identification [20]. PCR requires cycling of temperatures; denaturation at $90-95^{\circ}$ C, annealing at $55-60^{\circ}$ C, and extension at $68-72^{\circ}$ C to achieve exponential amplification of target DNA using a unique set of oligonucleotides and a thermostable DNA polymerase [21]. The reaction is done in a thermal cycler which works on the principle of Peltier effect [22], the PCR amplicon is mixed with any of the DNA binding fluorescent dye such as ethidium bromide, gel red etc. and amplified DNA is visualized on a UV – transilluminator after its separation on agarose gel. The molecular size of the amplicon is calculated by comparing its position and corresponding band of DNA ladder on agarose gel, DNA ladder contains regularly spaced DNA bands of known intensity and sizes [23].

In RT-PCR (Reverse Transcriptase - polymerase chain reaction) reaction, RNA is first converted to cDNA using reverse transcriptase enzyme and random hexamers or oligo-dT primers. The resultant cDNA is used as template for PCR amplification using gene specific primers. Amplification of specific segment of RNA could be done using RT-PCR, and the amplified PCR products could be visualized on UVtransilluminator [24]. This method of PCR amplification of RNA (through cDNA) has been routinely used in several molecular biology laboratories. Various methods can be used for analysis of DNA fragments size distribution as alternative to commonly used agarose gel electrophoresis which includes chip-based electrophoresis, and capillary electrophoresis [25]. The Bioanalyzer is the first commercially available system which employ chip-based separation technology to separate nucleic acids. The LabChip works on principle of capillary electrophoresis to separates nucleic acid fragments in a chip with microfabricated channels which also automates the detection as well as online data evaluation. This chip based electrophoresis system is widely used for determining the molecular size and quantity of DNA fragments [26-27]. Analysis of PCR products with the bioanalyzer yields several important advantages compared to traditional slab gel electrophoresis as it sizes and quantitates 12 samples on a disposable chip in approximately 30 min. Due to short separation channel and a high electrical field strength the speed of analysis is significantly increased compared to slab gel electrophoresis [27]. This high speed of analysis results in an increased sample throughput. The instrument is equipped with a fluorescence detection system resulting in superior detection sensitivity [27].

In present study, we optimized the multiplex PCR conditions directly from RNA with three SARS-CoV-2 genes namely; E gene, N gene, and M gene corresponding to envelope protein (E), nucleocapsid

protein (NC), and membrane protein (M) respectively. Multiplex PCR products can be visualized digitally on computer using Bioanalyzer. This optimized method is helpful detecting the presence of SARS-CoV-2 in one-step directly from RNA. Therefore, this method is cost effective and less time-consuming. It can be easily applied to small molecular biology laboratories having the basal level 2 facility. This method can be used as a toolkit for COVID detection.

Materials and Methods

Collection of samples and Isolation of viral RNA

Naso-pharyngeal swabs were collected and stored in Viral Transport Medium (VTM) as per the standard procedures prescribed by the World Health Organization (WHO) and the Indian Council of Medical Research (ICMR) [28-29]. Testing of samples for COVID-19 were made by following the appropriate ethical guidelines and required consent. Total RNA was isolated from VTM using MagMax RNA isolation kit by following manufacturer's instructions. RNA was quantified using NanoDropTM spectrophotometer. RNA was either used immediately for PCR based assays or stored at -70°C, until further use.

Single step reverse transcription (RT) and PCR amplification

To do the multiplex PCR, primer sets for three genes were designed from SARS-CoV-2 genome. The detailed list of primers for partial amplification of N, M, and E genes of SARS-CoV-2 are given in Table 1. These primers were synthesized using phosphoramidite method [30]. A primer set was also designed for partial amplification of human beta-actin gene (ACTB) which was used as positive control to check the quality of purified RNA from swab (Table 2). For a single sample, PCR was done in two individual tubes. One tube contained mix of six oligonucleotides called VPM (Viral Primer Mix), and another tube contained mix of two oligonucleotides called CPM (Control Primer Mix). The details of 'viral primer mix' is listed in Table 1, and the details of 'control primer mix' is listed in Table 2. A positive viral template control (VTC) and a negative no template control (NTC) assay was carried out in each experimental run. For VTC, 1.5 µL of control templates were used, while for NTC, nuclease free water was used instead of template. 3.0 µL of viral RNA was added to a 20 µL reaction mixture containing 2.0 µL of 10x VPM or CPM, 5 µL 4X master mix for one-step PCR (from RNA), and 10.0 µL of nuclease free water. Final concentration of 'N' and 'M' primers was 250 pmol each, and of 'E' primer was 400 pmol respectively. To make easier reaction set-up, 10x stock of VPM was made by adding the 2.5 µL each of N and M primers, and 4.0 µL of E primers from 100 µM stock, and final volume made to 100 µL. During reaction set-up, 2.0 µL from 10x VPM stock was used in a total reaction volume of 20 µL for performing multiplex viral PCR. Similarly, control reaction mix (20 uL) for ACTB was done by adding 2.0 µL from 10x CPM stock. This stock was made by adding 5.0 µL of ACTB 100 µM stock. The final concentration of primer in final PCR reaction mix was 500 pmol. Reactions were carried out in normal thermal cycler. Various permutation and combinations of primer concentration were tried for multiplex PCR and the best results were obtained following thermal cycling conditions: 25° C for 2 min, 53° C for 10 min, 95° C for 2 min, [95° C for 3 sec., 60° C for 30 seconds] X 40 cycles.

Name of the primer	Sequence of the primers used for PCR amplification	Length of the primer (nt)		Amplification target	Nucleotide position in (NCBI acc no. NC_045512.2)	
		(111)			Start	End
M_flank_Left	TGGCTCAGCTACTTCATTGC	20	373	Partial ORF of M gene	26796	26815
M_flank_Right	TGTCACTGCTACTGGAATGGTC	22			27147	27168

N_flank_Left_1	CTCTTGCTTTGCTGCTGCTT	20	501	Partial ORF of	28926	28945
N_flank_Right_1	TCTGCGGTAAGGCTTGAGTT	20		N gene	29407	29426
E_flank_Left_1	CACACAATCGACGGTTCATC	20		Partial ORF of E gene with 104	26131	26150
E_flank_Right_1	CCAGAAGATCAGGAACTCTAG	21	337	bp flank at 5'end	26447	26467

 Table 1 List of oligonucleotide primers used for PCR amplification of partial M, N, and E gene of the viral genome. Length of each primers, product size of the amplification, and location of the primers in the genome of SARS-CoV-2 (NC_045512.2) is showed in the table. The table also showed amplification target, i.e., the region of viral genome which was amplified by each primer pair. Mix of all these primers are represented in the following text as "viral primer mix"

Oligo name	Sequence of the primers	Size of amplicon and gene
ActnB_H1F	CATCGAGCACGGCATCGTCAC	436 bp
ActnB_H1F	CTTCTCCTTAATGTCTCGCAC	

 Table 2 Nucleotide sequence of the primers used for amplification of partial human beta-Actin gene. The mix of these two primers are named as "control primer mix"

Product visualization:

In 10 μ L of PCR products 1 μ L of gel red DNA visualization dye (Sigma-Aldrich) was added and products were separated on 2% agarose gel (in 1X TAE buffer). 100 kb plus DNA ladder (New England Biolabs) was used to determine size of various amplicons. A gel doc system (BIORAD) was used to visualize the gel.

Data analysis in automated electrophoresis:

Microfluidics-based electrophoresis system namely Bioanalyzer (Agilent 2100) is used for analysis of the PCR products. Optimization of the process were done as per manufacturer's instruction to achieve faster analysis, less hands-on activities, and analysis report preparation.

Sample preparation and loading PCR products on LabChip (Agilent): Analysis of PCR products was done using an Agilent DNA 1000 kit (Bioanalyzer) using 2100 Expert Software. The instrument uses a 16 well DNA LabChip (Fig. S1), where the PCR products were loaded as per the manufacturer's instructions.

Development of control plasmids for partial viral genes

To develop the DNA library and positive controls for future experimental validation, Phusion® high-fidelity PCR master mix with HF buffer was used for amplification of partial fragments of N, E, and M genes using cDNA template [31], prepared from purified RNA from SARS-CoV-2 infected person swab. From same cDNA sample human control ACTB gene partial fragment was also amplified. CDNA was synthesized using the RevertAid cDNA synthesis kit by following the manufacturer's protocol. CDNA was diluted four times in nuclease-free water, and 4 µL of diluent was used as template for PCR synthesis of partial gene fragments of SARS-CoV-2. All the amplicons from viral genes; 'E' gene, 'N' gene, 'M' gene and, human control gene 'ACTB' were gel purified using QIAquick gel extraction kit and cloned in Zero blunt TOPO PCR cloning kit using the manufacturer's protocol. A molar vector to insert ratio of 1:5 was used for ligation, assembled products were transformed in chemically competent DH5á E. coli cells. Transformed colonies were screened on LB agar plates containing 50 µg/mL kanamycin [32]. Clones were initially confirmed for their integration in vector using M13 forward and reverse primers, and results were analysed by comparing the molecular sizes of respective amplicon with 100 kb plus DNA ladder.

All the three partial viral genes were amplified from cDNA individually (Fig. 6) and cloned in Zero blunt TOPO PCR cloning kit. Successful cloning was confirmed by sanger sequencing of cloned fragments. Further confirmation was done by restriction digestion using *EcoR1* (Fig. S2), which released the product of respective sizes for each of the partial gene. The plasmids were sequenced using M13 forward and M 13 reverse primers in 3730 DNA analyzer (ThermoFischer Scientific) using Big-dye terminator kit. The sequences were compared with the original viral nucleic acid to confirm accuracy.

Results and Discussion:

Specificity of the primers

Over 100 genomes of the SARS-CoV-2 were retrieved from NCBI database and subjected to multiple sequence alignment (MSA) to know how much variations are available among the genomes. Based on the alignments, we identified the conserved consensus sequences from various genes, and used as primers for amplification of partial N, E, and M genes of SARS-CoV-2. Detailed list of primers and their respective amplicon sizes are mentioned in the table 1. The nucleotide sequences of N, M, and E gene along with 200 bp flanking regions from both 3' and 5' ends were subjected to multiple sequence alignment studies.

RNA extraction

Total RNA from SARS-CoV-2 infected person was purified using MagMax RNA extraction kit. The quality and quantity of RNA was evaluated through nanodrop spectrophotometer by measuring the 260/280 ratio. The RNA sample having this ratio in between 1.9 to 2.1 was used for the study.

One-step multiplex PCR

We did the normal PCR of human control ACTB gene (436 bp) to check the quality of purified RNA (Fig. 1). It helped in understanding of all the steps in RNA isolation and protocol worked properly. After confirming the sample quality, total RNA was used as template for both viral multiplex and human control gene PCR. The Multiplex SARS-CoV-2 PCR product was separated on 2 % agarose gel, three distinct bands of respective sizes; 373 bp for M gene, 501 bp for N gene, and 337 bp for E gene were seen on agarose gel (Fig. 2).




Fig. 1 agarose gel electrophoresis of ACTB PCR products using 'control primer mix' showing amplified DNA band (436 bp) for all positive and negative samples. Lane 1-5 are SARS-CoV-2 positive, and Lane 6-10 are SARS-CoV-2 negative samples. Lane 11 is no template control sample where water was used as template




Fig. 2 SARS-CoV-2 multiplex PCR: agarose gel electrophoresis of SARS-CoV-2 multiplex PCR products using 'viral primer mix' showing three partial gene amplicons of 501, 373, and 337 bp respectively for N, M and E genes. Lane 1 to 10 are SARS-CoV-2 positive samples; lane 11 to 15 are SARS-CoV-2 negative samples. 'N' is the no template control where nuclease-free water was sued as template. M is 1 Kb Plus DNA ladder




Fig. 3 *A schematic presentation of the whole process explained stepwise here*

(1) sample collection followed by (2, 3, & 4) transport, aliquots and extraction. Extracted samples are then (5) quantified and good quality samples are (6) amplified in thermal cycler as describe above. Amplified PCR products are then (7) analyzed by any one or both methods described agarose gel based as well as bioanalyzer based. Expected results not obtained or any error occurred then whole (8) process can be repeated

Bioanalyzer based detection:

Analysis using digitalized platform of Bioanalyzer generated high-quality digital gel images on computer and showed the respective amplicon sizes [33]. It also showed intensity-based quantity of various viral gene bands in multiplex PCR (Fig. 2, 4). The Labchip accommodates wells for samples, gel and an external standard (ladder). To create interconnected networks among the wells, micro-channels were made in glass. A sieving polymer was filled in the micro-channels during chip preparation. Once the wells and channels are filled, the chip becomes an integrated electrical circuit. The 16-pin electrodes of the cartridge are arranged so that they fit into the wells of the chip. Each electrode is connected to an independent power supply that provides maximum control and flexibility. A voltage gradient like slab gel electrophoresis was used to drive DNA and RNA biomolecules electrophoretically. Molecules got separated based on size

because of the presence of a sieving polymer matrix and constant massto-charge ratio [34-35]. The detection is automatically performed by laser induced fluorescence (LIF) detection. Data is translated into gel-like images (bands) and electropherograms (peaks) where the X axis represent size and Y axis represents quantity of the PCR product. This principle was used to separate the SARS-CoV-2 multiplex PCR products using this digitalized platform. A standard curve of migration time versus molecule size is plotted with the help of a ladder that contains components of known sizes. Analysis of the samples containing SARS-CoV-2 virus (positive) produced 3 'viral PCR peaks' between 300 - 500 bp (Fig. 4a). Whereas the samples which does not contain the virus (negative) does not produced any peak between 300 - 500 bp region (Figure. 4b). The PCR products containing 'control primer mix' produced only single peak within 400 -450 bp in both positive and negative (Fig. 4c). Appearance of this peak ensured that RT and PCR reaction has worked properly in a single reaction tube. The general diagram showing the chip structure and its micro-fluidic design is shown (Fig.S1). the electropherogram produced after the digitalized gel electrophoresis in bioanalyzer DNA chip device are also shown (Fig 4, 5).




Fig. 4 Electropherogram generated in Agilent Bioanalyzer 2100 using DNA LabChip after analysis of the PCR products. from positive (a) and negative samples (b). Single tube RT and PCR reactions were done using 'viral primer mix' for a and b, and 'control primer mix' for c. (a) positive, as there are 2 - 3 peaks produced in 300 - 500 bp; (b) negative, as there are no peak between 300 - 500 bp; (c) control, single peak between 400 - 500 bp region ensure that RT and PCR reactions worked properly. For all figures X axis is size of the DNA (bp), Y axis is quantity of the DNA. The peaks at 15 and 1500 bp are internal control




Fig. 5 Graphical representations of the samples analyzed by microfluidic DNA LabChip (Bioanalyzer). (a) Peak and representative gel image of ladder (15 – 1500 bp); (b) size, concentration, and molarity of the DNA fragments of the ladder which can be used for quantitative assay; (c) Representative gel image of the ladder, negative samples (lanes: N1, N2, N3) and positive samples (Lanes: P1, P3, P5) generated by the 2100 Expert software. Electropherogram of representative negative samples named as N1, N2, N3 showing only control peaks of 15 bp and 1500 bp, whereas representative positive samples named as P1, P3, P5 showing 2 – 3 peaks (within 300 – 500 bp region) along with control peaks of 15 and 1500 bp.

Control plasmids for validation of primers:

Partial DNA region of envelope protein (E), nucleocapsid protein (N), and membrane protein (M) of SARS-CoV-2 were cloned in plasmid vector used as positive control in PCR analysis of the patient samples. These control DNA were used to validate the reaction condition and quality assay of the primer-mix used in the study (Fig. 6). In the quality assay the primer pair or mix is expected to generate PCR products of 436 bp for actinB gene, 337 bp for E gene, 373 BP for M gene, 501 bp for N gene (Fig. 6).





Fig. 6 PCR amplification of partial viral genes from cDNA of SARS-CoV-2 using Phusion master mix to generate blunt end products for cloning. 1: ACTB (436 bp); 2: E gene (337 bp); 3: M gene (373 BP); 4: N gene (501 bp).

Conclusion:


As there has been a sudden increase in the COVID-19 cases worldwide it becomes necessary to have efficient testing facility to overcome and control the pandemic situation. Various alternative methods and assays for RT PCR are now commercially available in the market but not all are that efficient in detection of viral infection. Though antibody testing is a rapid method for detection but have certain limitations as it detects the antibodies a week period after the infection and till that time, infected person can spread infection to others. As per several reports, antigen test is also giving about 50-60% accurate results and not reliable for sample with low viral load. As there are challenges in developing specific antibodies for COVID-19, antigen test becomes less favorite for testing. Though RT PCR known to be gold standard for testing COVID-19 detection, its sensitivity gets affected by low viral load into the patient sample [36]. This assay development involves huge investment as it requires expensive instruments and skilled person to operate so increases overall costing of test, small laboratories and institutions cannot afford it. By contrast, sensitivity of our multiplex PCR assay did not have any issue due to low viral load and found more sensitive than standard RT-PCR. Developed method to be useful in diagnosis of SARS-CoV-2 in small laboratories or residential on a low cost. It can be utilized for regular testing of employees working, or people residing in the small housing society. This method can do low throughput in short time, which reduces the cost as well. The method can be further improvised to perform high throughput and save more time and cost.

Supplementary Material (ESM)

Supplementary Fig. S1 Image of a DNA labChip of Agilent 2100 bioanalyzer used for detection of PCR products (adopted from Agilent Social Hub). (A) specification and surface design of the LabChip, (B) micro-fluidic design of the LabChip.



Supplementary Fig. S2 Restriction digestion of two plasmids each of four genes (one human control and three viral) was done using *EcoR1*. Expected sizes of fragment release were obtained.



Funding Resources

The current study was funded by Reliance Industries Limited

Conflict of Interest

The authors declare they have no conflict of interest.

```
Auctores Publishing - Volume 1(4)-019 www.auctoresonline.org
```

Acknowledgements

The authors thank Dr. Ipsita Dutta, Dr. Yash Gupte, Dr. Smita Patil for their valuable support and Reliance Life Science for providing infrastructural and logistic support during this study. We also thank to RIL – IP team for review of the manuscript and providing approval for publication.

Compliance with ethical standards

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

References

- Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. (2020) Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 5(7):831–840. doi:10.1001/jamacardio.2020.1286
- 2 Chen, B., Tian, EK., He, B. et al. (2020) Overview of lethal human coronaviruses. Sig Transduct Target Ther 5, 89.
- Li, H., Liu, S. M., Yu, X. H., Tang, S. L., & Tang, C. K. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. International journal of antimicrobial agents, 55(5), 105951.
- World Health Organization. (2020). Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020. World Health Organization. License: CC BY-NC-SA 3.0 IGO
- Oran DP, Topol EJ. (2020) Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. [PMID:32491919]
- Ferric C Fang, Samia N Naccache, Alexander L Greninger, (2020) The Laboratory Diagnosis of Coronavirus Disease 2019— Frequently Asked Questions, Clinical Infectious Diseases, Volume 71, Issue 11, Pages 2996–3001.
- Faustini SE, Jossi SE, Perez-Toledo M, et al. (2020) Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection. medRxiv, [Preprint] 2020.06.16.20133025.
- Huang, A.T., Garcia-Carreras, B., Hitchings, M.D.T. et al. (2020) A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun 11, 4704.
- Long, QX., Liu, BZ., Deng, HJ. et al. (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845–848.
- Mustafa K. Ozcurumez, Andreas Ambrosch, et al. (2020) SARS-CoV-2 antibody testing—questions to be asked, Journal of Allergy and Clinical Immunology, Volume 146, Issue 1, Pages 35-43, ISSN 0091-6749.
- Hou, H., Wang, T., Zhang, B., Luo, Y., Mao, L., Wang, F., Wu, S. and Sun, Z. (2020), Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol, 9: e1136.
- Jayamohan, H., Lambert, C.J., Sant, H.J. et al. SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations. Anal Bioanal Chem 413, 49–71 (2021).
- Kumar S., Nyodu R., Maurya V.K., Saxena S.K. (2020) Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In: Saxena S. (eds) Coronavirus Disease 2019 (COVID-19). Medical Virology: From Pathogenesis to Disease Control. Springer, Singapore.
- Marra MA, Jones SJ, Astell CR, et al. (2003) The Genome sequence of the SARS-associated coronavirus. Science. 300(5624):1399-1404. Published online 1 May 2003; doi:10.1126/science.1085953

- Indwiani Astuti, Ysrafil, (2020) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Volume 14, Issue 4, Pages 407-412,
- Chen, Y, Liu, Q, Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92: 418–423.
- Sairaj Satarker, Madhavan Nampoothiri, (2020) Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2, Archives of Medical Research, Volume 51, Issue 6, Pages 482-491.
- Bhadra, B., Jalali, S., & Dasgupta, S. (2020). Mutation analysis of structural and non-structural proteins indicated that the death rate of COVID-19 pandemic may significantly reduce by the end of 2020. OSF Preprint
- Sanjuan, R., Domingo-Calap, P. (2016). Mechanisms of viral mutation. Cellular and molecular life sciences: CMLS, 73(23), 4433–4448.
- 20. VALONES, Marcela Agne Alves et al. (2009) Principles and applications of polymerase chain reaction in medical diagnostic fields: a review. Braz. J. Microbiol. [online]. vol.40, n.1, pp.1-11. ISSN 1678-4405.
- Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., & Erlich, H. (1986). Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor symposia on quantitative biology, 51 Pt 1, 263–273.
- Xianbo Qiu and Jingqi Yuan, (2005) "Temperature Control for PCR Thermocyclers Based on Peltier-Effect Thermoelectric," IEEE Engineering in Medicine and Biology 27th Annual Conference, Shanghai, 2005, pp. 7509-7512, doi: 10.1109/IEMBS.2005.1616249.
- 23. Lee, P. Y., Costumbrado, J., Hsu, C. Y., Kim, Y. H. (2012) Agarose Gel Electrophoresis for the Separation of DNA Fragments. J. Vis. Exp. (62), e3923, doi:10.3791/3923
- Carter M, Shieh J. (2015) Molecular cloning and recombinant DNA technology. In: Carter Matt, Jennifer shieh (ed) guide to research techniques in neuroscience. 2nd edn. Academic Press. p. 219e37.
- Ou, X, Chen, P, Huang, X, Li, S, Liu, B- F. (2020) Microfluidic chip electrophoresis for biochemical analysis. J Sep Sci; 43: 258–270.
- Hathaway LJ, Brugger S, Martynova A, Aebi S, Mühlemann K. (2007) Use of the Agilent 2100 bioanalyzer for rapid and reproducible molecular typing of Streptococcus pneumoniae. J Clin Microbiol. 45(3):803-9. doi: 10.1128/JCM.02169-06.
- Nachamkin, I., Panaro, N. J., Li, M., Ung, H., Yuen, P. K., Kricka, L. J., & Wilding, P. (2001). Agilent 2100 bioanalyzer for restriction fragment length polymorphism analysis of the Campylobacter jejuni flagellin gene. Journal of clinical microbiology, 39(2), 754–757.
- Y.K. Gurav (2020) Specimen Collection, Packaging and Transport Guidelines for 2019 novel Coronavirus. Accessed on 12 Nov 2020
- 29. World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases. Interim guidance. Available from: accessed on 09 Dec 2020
- Hao, M., Qiao, J., & Qi, H. (2020). Current and Emerging Methods for the Synthesis of Single-Stranded DNA. *Genes*, 11(2), 116.
- 31. Choudhary, M. L., Vipat, V., Jadhav, S., Basu, A., Cherian, S., Abraham, P., & Potdar, V. A. (2020). Development of *in vitro* transcribed RNA as positive control for laboratory

diagnosis of SARS-CoV-2 in India. The Indian journal of medical research, 151(2 & 3), 251–254.

- Kostylev M, Otwell AE, Richardson RE, Suzuki Y (2015) Cloning Should Be Simple: Escherichia coli DH5α-Mediated Assembly of Multiple DNA Fragments with Short End Homologies. PLoS ONE 10(9): e0137466.
- Odilo Mueller (2000) Quantitative analysis of PCR fragments with the Agilent 2100 Bioanalyzer: Application Note Accessed on 19 Dec 2020
- Mueller, O., Hahnenberger, K., Dittmann, M., Yee, H., Dubrow, R., Nagle, R. and Ilsley, D. (2000), A microfluidic system for high-speed reproducible DNA sizing and quantitation. ELECTROPHORESIS, 21: 128-134.
- Meike Kuschel, Carsten Buhlmann, and Tobias Preckel (2005) High-throughput Protein and DNA Analysis Based on Microfluidic On-chip Electrophoresis Accessed on 19 Dec 2020
- de Kock, R., Baselmans, M., Scharnhorst, V. et al. (2020) Sensitive detection and quantification of SARS-CoV-2 by multiplex droplet digital RT-PCR. Eur J Clin Microbiol Infect Dis.